Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692715 | 0.85 | HPGD (0.39) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL40461 | 0.79 | MAPT (0.43) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL3070394 | 0.76 | MAPT (0.48) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL141775 | 0.69 | HPGD (0.50) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL3081111 | 0.67 | MAPT (0.48) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL10099509 | 0.67 | HPGD (0.41) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL10831154 | 0.65 | SMN1; SMN2 (0.45) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL8240702 | 0.65 | — | — | |
| SCHEMBL5672126 | 0.65 | MAPT (0.45) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL5695276 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | MIRECA MEDICINES GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4399215-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | Mireca Medicines GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023031481-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2344514-A2 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010028079-A2 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20040204325-A1 | Transmission fluid compositions for automobiles | NIPPON OIL CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-20040192562-A1 | Lubricating oil composition | NIPPON OIL CORPORATION | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | GMPS, CGAS, AMPD3 | HPGD 299/4885MAPT 4754/4885SMN1; SMN2 2930/4885 |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | IFNAR1, DDX18, STING1 | HPGD 3627/4885MAPT 4731/4885SMN1; SMN2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.